Newsfiscal.ai
Milestone Pharmaceuticals Announces Upcoming Presentations of CARDAMYST Data
· Published
Article summary
Milestone Pharmaceuticals announced that it will present new data and program updates for its FDA-approved CARDAMYST (etripamil) nasal spray at three upcoming cardiovascular medical conferences.
An excerpt from the original article.Related companies
Analyzed by WAPE AI.
Preparing English content…
Comments —
Loading comments…